Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 7

1.

Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O.

Bruehlmeier M, Roelcke U, Schubiger PA, Ametamey SM.

J Nucl Med. 2004 Nov;45(11):1851-9.

2.

Synthesis and evaluation of 4-bromo-1-(3-[18F]fluoropropyl)-2-nitroimidazole with a low energy LUMO orbital designed as brain hypoxia-targeting imaging agent.

Yamamoto F, Aoki M, Furusawa Y, Ando K, Kuwabara Y, Masuda K, Sasaki S, Maeda M.

Biol Pharm Bull. 2002 May;25(5):616-21.

3.

Characterization of [18F]fluoroetanidazole, a new radiopharmaceutical for detecting tumor hypoxia.

Rasey JS, Hofstrand PD, Chin LK, Tewson TJ.

J Nucl Med. 1999 Jun;40(6):1072-9.

4.

Synthesis and characterization of lipophilic 1-[18F]fluoroalkyl-2-nitroimidazoles for imaging hypoxia.

Yamamoto F, Oka H, Antoku S, Ichiya Y, Masuda K, Maeda M.

Biol Pharm Bull. 1999 Jun;22(6):590-7.

PMID:
10408232
5.

Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia.

Hodgkiss RJ.

Anticancer Drug Des. 1998 Sep;13(6):687-702. Review.

PMID:
9755725
6.

Development of F-18-labeled fluoroerythronitroimidazole as a PET agent for imaging tumor hypoxia.

Yang DJ, Wallace S, Cherif A, Li C, Gretzer MB, Kim EE, Podoloff DA.

Radiology. 1995 Mar;194(3):795-800.

PMID:
7862981
7.

Nitroimidazoles and imaging hypoxia.

Nunn A, Linder K, Strauss HW.

Eur J Nucl Med. 1995 Mar;22(3):265-80. Review.

PMID:
7789400

Supplemental Content

Support Center